---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-044616"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:38:35.802032+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Therapeutics PAO Edmund Dunn to retire; Matthew Bowen appointed successor

## Summary
- Edmund Dunn, SVP, Corporate Controller and PAO, to retire effective April 3, 2026; no severance or disagreement.
- Matthew Bowen, age 37, promoted from Director, Finance to Corporate Controller and PAO effective April 3, 2026.
- Bowen joined Monte Rosa in June 2021 post-IPO; previously 7 years at Ernst & Young in audit.
- Bowen holds BS and MS in Accounting from Bryant University and is a licensed CPA in Massachusetts.
- No family relationships or related party transactions with Bowen; no arrangements for promotion.

## SEC filing metadata
- accession: 0001193125-26-044616
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526044616/0001193125-26-044616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526044616/glue-20260209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-044616
- JSON: https://secwatch.observer/filing/0001193125-26-044616.json
- Plain text: https://secwatch.observer/filing/0001193125-26-044616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.